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INTRODUCTION: Chronic hepatitis B (CHB) remains amajor worldwide public health concern. Besifovir dipivoxilmaleate
(BSV) is a new promising treatment for CHB. However, long-term efficacy and safety have not yet been
evaluated. Therefore, the goal of the study is to determine the antiviral efficacy and safety of BSV
treatment over a 144-week duration (BSV-BSV) in comparisonwith those of a sequential treatment with
tenofovir disoproxil fumarate (TDF) followed by a 96-week duration BSV administration (TDF-BSV).
METHODS: After 48weeks of a double-blind comparison between BSV and TDF treatments, patients continued the
open-label BSV study.We evaluated antiviral efficacy and drug safety up to 144weeks for BSV-BSV and
TDF-BSV groups. The primary endpoint was a virological response (hepatitis B virus DNA < 69 IU/mL).
RESULTS: Among the 197 patients enrolled, 170 and 158 patients entered the second-year and third-year open-
label phase extensional study, respectively, whereas 153 patients completed the 144-week follow-up.
The virological response rate over the 144-week period was 87.7% and 92.1% in BSV-BSV and TDF-
BSV groups, respectively (P5 0.36). The rates of ALT normalization and HBeAg seroconversion were
similar between the groups. No drug-resistant mutations to BSV were noted. Bone mineral density and
renal function were well preserved in the BSV-BSV group and were significantly improved after
switching therapy in TDF-BSV patients.
DISCUSSION: This extensional study of a phase 3 trial (NCT01937806) suggests that BSV treatment is efficacious
and safe for long-term use in treatment-naı̈ve and TDF-experienced patients with CHB.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/AJG/B485, http://links.lww.com/AJG/B491
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INTRODUCTION
Chronic hepatitis B (CHB) remains a major worldwide public
health problem despite the presence of effective vaccines and
potent antivirals (1,2). Although the prevalence of chronic
hepatitis B virus (HBV) infection was significantly reduced after
the introduction of a universal HBV vaccination program in
many Asian countries, new cases of HBV infection are still
reported, even in low-prevalence areas (3–5). In South Korea,
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CHB still has a significant impact on public health, considering
that the hepatitis B surface antigen (HBsAg) is detected in
60%–70% of patients with liver cirrhosis (5) and 65%–75% of
patients with hepatocellular carcinoma (HCC) (6,7).
Currently, second-generation nucleos(t)ide analogs (NAs),
such as entecavir, tenofovir disoproxil fumarate (TDF), and
tenofovir alafenamide fumarate (TAF), which have high genetic
barriers to resistance and potent viral suppression activity, are
used as primary treatments of CHB (8).
Besifovir dipivoxil maleate (BSV), an acyclic nucleotide
phosphonate (a guanosine monophosphate), has been tested in
several phase Ia/IIb studies and has shown potent suppression of
Table 1. Baseline characteristics of the study subjects
BSV-BSV (n 5 81) TDF-BSV (n 5 76) P Value
Male 54 (66.7) 49 (64.5) 0.77
Age, yr 46.00 (10.9) 43.99 (9.7) 0.22
HBeAg positive 51 (63.0) 43 (56.6) 0.87
HBV genotype 0.41
A 1 (1.2) 0 (0.0)
C 79 (97.5) 75 (98.7)
D 0 (0.0) 1 (1.3)
Not determined 1 (1.2) 0 (0.0)
HBV DNA (log10 IU/mL) 6.3 (1.7) 6.5 (1.5) 0.62
ALT (U/L) 106.15 (101.6) 128.41 (141.8) 0.36
ALT. ULN by central lab criteriaa 78 (96.3) 71 (93.4) 0.48
ALT normalization by central lab criteria 3 (3.7) 5 (6.6)
eGFR by MDRD (mL/min) 89.74 (14.8) 91.97 (13.7) 0.36
Creatinine (mg/dL) 0.86 (0.2) 0.84 (0.1) 0.43
Phosphate (mg/dL) 3.54 (0.5) 3.44 (0.6) 0.29
Total hip bone mineral density clinical
status, nb
70 58 0.80
Normal (T-score$ 21.0) 58/70 (82.9) 49/58 (84.5)
Osteopenia (22.5# T-score ,21.0) 12/70 (17.1) 9/58 (15.5)
Osteoporosis (T-score ,22.5) 0 (0.0) 0 (0.0)
Data not collected 11 18
Spine bone mineral density clinical status, nc 73 62 0.67
Normal (T-score$ 21.0) 50/73 (68.5) 40/62 (64.5)
Osteopenia (22.5# T-score ,21.0) 19/73 (26.0) 20/62 (32.3)
Osteoporosis (T-score ,22.5) 4/73 (5.5) 2/62 (3.2)
Data not collected 8 14
Concurrent history 64 (79.0) 50 (65.8) 0.06
Mild renal impairmentc 48 (59.3) 40 (52.6) 0.40
Cirrhosis 19 (23.5) 14 (18.4) 0.44
Cardiovascular disease 0 (0.0) 0 (0.0) —
Diabetes mellitus 12 (12.8) 4 (4.3) 0.05
Hypertension 11 (11.7) 10 (10.8) 0.94
Hyperlipidemia 2 (2.1) 2 (2.2) 1.00
Prior antiviral therapy 0 (0.0) 1 (1.1)a 0.48
Data are number (%), n/N (%), ormean (SD) unless otherwise stated.P value: 2-sample t test orWilcoxon rank-sum test for continuous variables and x2 test or Fisher exact
test for categorical variables.
ALT, alanine aminotransferase;BMD, bonemineral density; BMD, bonemineral density; BSV, besifovir dipivoxilmaleate; eGFR, estimated glomerular filtration rate; HBeAg,
hepatitis B e antigen; HBV, hepatitis B virus; MDRD, modification of diet in renal disease; TDF, tenofivir disoproxil fumarate; ULN, upper limit of normal.
aThirty-three U/L for women, 41 U/L for men.
bFor BMD, some data were not collected.
c50 # eGFR, 90 (mL/min).





HBV replication (9–12). BSV was approved for the treatment
of chronic HBV infection inMay 2017 in South Korea after we
performed a randomized, multicenter, double-blind phase 3
study comparing the efficacy and safety of once-daily treat-
ment with BSV vs TDF for 48 weeks in naı̈ve patients with
CHB (13). We reported that BSV elicited minor side effects on
the kidneys and bones, with antiviral efficacy comparable with
that of TDF over 48 weeks of treatment (13). This study was
planned as an open-label follow-up study in which patients
receive BSV for 7 years after initial treatment with BSV
or TDF.
The aim of this study was to compare the antiviral efficacy and
safety of a BSV solo treatment (BSV-BSV) over a 144-week period




This experimental study took over a 144-week period of treating
patients with hepatitis B in South Korea. The first 48 weeks cor-
responded to a double-blind, randomized, multicenter,
noninferiority, controlled trial comparing BSV (Ildong Phar-
maceutical, Seoul, Korea) with TDF (Gilead Sciences, Foster City,
CA) treatments. Patients from that study who were suited to
continue a single-arm, open-label trial received BSV for an ad-
ditional 96weeks.Written informed consent for both the 48-week
initial phase and the open-label phase was obtained from all study
participants. This study was conducted with the approval of the
Human Research Ethics Committee in the 22 participating hos-
pitals in the Republic of Korea, following the Declaration of
Helsinki and all other applicable guidelines, laws, and regulations.
Detailed descriptions of the study design, sample size estimates,
eligibility criteria, and overall study population have been pre-
viously reported (13).
Bone mineral density, noninvasive fibrosis test, and re-
sistance surveillance were regularly performed (see Supple-
mentary Material, Supplementary Digital Content 1, http://
links.lww.com/AJG/B491). Particularly, FIB-4 and aspartate
aminotransferase-to-platelet ratio indexes (APRI) were an-
nually estimated to assess liver fibrosis (see Table, Supple-
mentary Digital Content 2 for formula used, http://links.lww.
com/AJG/B485).
Figure 1. Patient disposition. BSV, besifovir dipivoxil maleate; CPK, creatinine phosphokinase; FAS, full analysis set; HBV, hepatitis B virus; HCC,
hepatocellular carcinoma; IP, investigational product; PPS, per-protocol set; TDF, tenofovir disoproxil fumarate.
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Subjects
Patients with CHB younger than 20 years of age and HBsAg-
positive for at least 6 months before screening were eligible. Sub-
jects with HBV DNA levels.17,241 IU/mL (13 105 copies/mL)
and. 1,724 IU/mL (13 104 copies/mL), who tested positive and
negative for hepatitis B e-antigen (HBeAg), respectively, were
randomized 1:1 into BSV or TDF treatment groups for 48 weeks.
Tomaintain blinding of investigators and subjects, subjects in the
BSV group were given BSV 150 mg with L-carnitine 660 mg as
a supplementandTDFplacebo,whereas those in theTDFgroupwere
givenTDF300mgwith L-carnitine as a BSVplacebo.After 48weeks,
the patients continued on BSV or were switched to BSV 150mgwith
L-carnitine 660mg during the open-label phase for up to 144 weeks.
Endpoints
The efficacy endpoint was the proportion of subjects with a viro-
logical response, defined as HBV DNA ,69 IU/mL at week 144.
Other efficacy and safety endpoints, including the proportions of
subjects with undetectable HBV DNA levels (,20 IU/mL),
changes of serum HBV DNA levels, HBsAg or HBeAg serocon-
version, alanine aminotransferase (ALT) normalization, drug re-
sistance, adverse events (AEs), bone mineral density (BMD), renal
function-related parameters, fibrosis parameters, incidences of
HCC, and other abnormalities, were assessed.
Laboratory tests and assessments
All laboratory data during the trial were collected at 12-week
intervals via the Central Lab (GC abs, Yongin, Korea). HBVDNA
quantification was performed using a COBAS AmpliPrep/
TaqMan test (Roche Diagnostics, Indianapolis, IN) with
a lower detection limit of 20 IU/mL. Other laboratory methods
were followed as previously reported (13).
Bone mineral density, non-invasive fibrosis test, and resistance
surveillance were regularly performed (see Supplementary
Material, Supplementary Digital Content 1, http://links.lww.com/
AJG/B491). Particularly, FIB-4 and aspartate aminotransferase-to-
platelet ratio indexes (APRI)were annually estimated to assess liver
Table 2. Virological, serological, and biochemical responses
48 wk 144 wk
BSV (n5 97) TDF (n5 95) P Value BSV-BSV (n 5 81) TDF-BSV (n 5 76) P Value
HBV DNA ,69 IU/mL 76 (78.4) 80 (84.2) 0.30 71 (87.7) 70 (92.1) 0.36
HBV DNA ,20 IU/mL 60 (61.9) 65 (68.4) 0.34 65 (80.3) 65 (85.5) 0.38
HBeAg loss, n/N (%)a 5/53 (9.4) 3/50 (6.0) 0.72 10/50 (20.0) 13/41 (31.7) 0.20
HBeAg seroconversion, n/N (%)a 3/53 (5.7) 1/50 (2.0) 0.62 4/50 (8.0) 5/41 (12.2) 0.73
HBsAg loss, n/N (%)b 0/87 (0.0) 1/87 (1.1) 1.00 0/79 (0.0) 1/71 (1.4) 0.47
HBsAg seroconversion, n/N (%)b 0/87 (0.0) 0/87 (0) — 0/79 (0.0) 1/71 (1.4) 0.47
ALT normalization, n (%)c 69 (71.1) 71 (74.7) 0.57 66 (81.5) 67 (88.2) 0.25
Data are expressed as n (%), unless stated otherwise. P value: Pearson x2 test/Fisher exact test.
ALT, alanine aminotransferase; BSV, besifovir dipivoxil maleate; HBeAg, hepatitis B e antigen; HBsAg, HBeAg, hepatitis B surface antigen; TDF, tenofovir disoproxil
fumarate.
aAmong HBeAg-seropositive patients at baseline.
bAmong HBsAg-seropositive patients at baseline.
cAmong patients with baseline ALT levels above the central lab normal range (0–41 U/L for males and 0–33 U/L for females).
Figure 2. Viral suppression by study visit. (a) Proportions of patients with HBV DNA,69 IU/mL as determined by the FAS. (b) Proportions of patients with
HBVDNA,20 IU/mLas determinedby FAS.Bars represent 95%confidence intervals. BSV, besifovir dipivoxilmaleate; FAS, full analysis set; HBV, hepatitis
B virus; TDF, tenofovir disoproxil fumarate.





fibrosis (see Table, Supplementary Digital Content 2 for formula
used, http://links.lww.com/AJG/B485).
Statistical analysis
For primary efficacy analysis, proportions of patients with HBV
DNA ,69 IU/mL were determined using the full analysis set
(FAS), which included all patients who received at least one in-
vestigational product and completed at least one efficacy evalu-
ation. Per-protocol analysis was performed after excluding
consent withdrawals and major protocol violators from the FAS
population.
Differences in the baseline characteristics and secondary
endpoints between the groups were tested using an independent
2-sample t test or Wilcoxon rank-sum test for continuous vari-
ables and a x2 test or Fisher exact test for categorical variables.We




Of 197 patients who were initially randomly assigned, 170 (86%)
entered the second year, 158 (80%) entered the third year ex-
tensional study, andfinally 153 completed all 144weeks of follow-
up (Figure 1). Of 157 patients (81 in BSV-BSV and 76 in TDF-
BSV) who qualified for the FAS at 144 weeks, 145 were included
for the PPS analysis. The baseline characteristics for both treat-
ment groups were well-balanced (Table 1). Considering both the
groups, 65.6% patients enrolled were men, with a mean age of 45
years. Subjects positive for HBeAg represented 63.0% in the BSV-
BSV group and 56.6% in the TDF-BSV group, with the most
common HBV genotype being C. For BSV-BSV and TDF-BSV
groups, the means of HBV DNA at the baseline were 6.3 and 6.5
log10 IU/mL, respectively. More than half of the patients showed
a normal T-score in the hip and/or spine at the baseline
(64.5%–84.5%). Although the BSV-BSV group wasmore likely to
have concurrent histories, including cirrhosis and diabetes mel-
litus, at the baseline, no statistically significant differences were
noted between the groups.
Efficacy
Virological response. The rate of virological response (HBV
DNA , 69 IU/mL) in BSV-BSV was 87.7% (71/81), whereas
92.1% (70/76) of patients who switched the treatment fromTDF
to BSV responded up to 144 weeks, indicating that the BSV-BSV
group met the efficacy endpoint of noninferiority with pre-
determined 215% margin to BSV-TDF according to the FAS
(lower bound 95% CI 5 213.8%, P 5 0.36) (Table 2 and
Figure 2a). The complete virological response with the lower
limit of HBV DNA quantification (,20 IU/mL) was 80.3% (65/
81) among the BSV-BSVpatients and 85.5% (65/76) in the TDF-
BSV group at week 144 (P 5 0.38) (Table 2 and Figure 2b).
Similar results were observed in the PPS (see Figure, Supple-
mentary Digital Content 3A, 3B, http://links.lww.com/AJG/
B485) (HBVDNA, 69 IU/mL, 92.1% vs 95.7%, P5 0.50; HBV
DNA , 20 IU/mL, 84.2% vs 88.4%, P 5 0.46; in BSV-BSV vs
TDF-BSV, respectively).
Antiviral responses from the baseline during every follow-up
visit until week 144 are shown in Figure 3. During the first 48
weeks, the degree of HBV DNA reduction was not significantly
different between the 2 groups (Figure 3a), except for at the end of
the first month. Mean HBV DNA decreased to ,2 log10 IU/mL
Figure 3.Antiviral responses by study visit (weeks). (a) Degree of HBVDNA reduction (log IU/mL). (b)MeanHBVDNA level (log IU/mL). ANOVA, analysis of
variance; BSV, besifovir dipivoxil maleate; HBV, hepatitis B virus; TDF, tenofovir disoproxil fumarate.
Table 3. Improvements in noninvasive fibrosis markers FIB-4 and
APRI indexes at 144 weeks
BSV-BSV (n5 81) TDF-BSV (n 5 76) P valuea P valueb
FIB-4
Baseline 2.12 (2.07) 1.92 (1.14) — —
144 wk 1.32 (0.76) 1.27 (0.83) — —
Change 20.80 (1.77) 20.65 (0.92) 0.79 0.54
P valuec ,0.0001 ,0.0001
APRI
Baseline 1.22 (1.31) 1.35 (1.32) — —
144 wk 0.40 (0.30) 0.39 (0.38) — —
Change 20.82 (1.33) 20.97 (1.31) 0.30 0.29
P valuec ,0.0001 ,0.0001
Data are expressed as mean (standard deviation), unless otherwise stated.
APRI, aspartate aminotransferase-to-platelet ratio index; BSV, besifovir dipivoxil
maleate; TDF, tenofovir disoproxil fumarate.
aBetween-group: Wilcoxon rank-sum test.
bBetween-group: mixed model with repeated measures (every 12 weeks
measurement).
cWithin-group: Wilcoxon signed-rank test.
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levels at week 24 and remained stable for 144 weeks (Figure 3b).
No significant differences between the 2 groups were observed
during the 144 weeks (Figure 3b).
Biochemical and serological responses. Among HBeAg-positive
patients, the cumulative incidences of HBeAg loss at 144 weeks
were 20.0% (10/50) in the BSV-BSV group and 31.7% (13/41) in
the TDF-BSV group (P 5 0.20). The incidences of HBeAg sero-
conversion were 8.0% (4/50) and 12.2% (5/41) in the BSV-BSV
and TDF-BSV groups, respectively (P 5 0.73). There was no
significant difference in HBeAg serological responses between
both groups (Table 2); only one patient (1.4%, 1/71) in the TDF-
BSV group showed HBsAg loss during the 144 weeks (Table 2).
ALT levels normalized in 81.5% (66/81) and 88.2% (67/76)
subjects in the BSV-BSV and TDF-BSV groups after 144 weeks,
with no significant difference between the groups (P 5 0.25)
(Table 2).
Subgroup analysis. Biochemical, serological, and virological
responses were separately evaluated in HBeAg-positive and
HBeAg-negative patients according to the baseline HBeAg status
for FAS and PPS (see Tables, Supplementary Digital Content 4
and 5, http://links.lww.com/AJG/B485; see Figure, Supplemen-
tary Digital Content 6, http://links.lww.com/AJG/B485).
In the FAS, all HBeAg-negative patients reached HBV DNA
,69 IU/mL at week 144. Only one patient in each group did not
achieve a complete virological response (HBVDNA, 20 IU/mL)
by week 144. There was no difference in virological response rates
among HBeAg-negative patients.
Among HBeAg-positive patients, the proportions who ach-
ievedHBVDNA,69 IU/mLwere 80.4% (41/51) in the BSV-BSV
and 86.1% (37/43) in the TDF-BSV group (P5 0.47). The rates of
HBV DNA ,20 IU/mL were 70.6% (36/51) and 76.7% (33/43),
respectively (P 5 0.50). There was no difference in virological
Table 4. Safety data
Variables
0–144 wk 96–144 wk
BSV (n 5 81) TDF (n5 76) BSV-BSV (n 5 81) TDF-BSV (n5 76)
Adverse events, n (%), [cases] 63 (77.8), [253] 56 (73.7), [209] 54 (66.7), [125] 42 (55.3), [95]
Adverse drug reactions 31 (38.3) 26 (34.2) 23 (28.4) 15 (19.7)
Serious adverse events 7 (8.6) 7 (9.2) 1 (1.2) 2 (2.6)
Serious adverse drug reactions 1 (1.2) 0 0 0
Death 0 0 0 0
Adverse events recorded in $3% of all
patients
Nasopharyngitis 14 (17.3) 14 (18.4) 3 (3.7) 4 (5.3)
Dyspepsia 8 (9.9) 10 (13.2) 1 (1.2) 1 (1.3)
Headache 6 (7.4) 3 (4.0) 1 (1.2) 1 (1.3)
Back pain 6 (7.4) 4 (5.3) 3 (3.7) 3 (4.0)
Fatigue 5 (6.2) 5 (6.6) 1 (1.2) 2 (2.6)
Pruritus 3 (3.7) 4 (5.3) 0 1 (1.3)
Gastritis 2 (2.5) 9 (11.8) 1 (1.2) 8 (10.5)
Nausea 5 (6.2) 1 (1.3) 0 0
ALT elevation 6 (7.4) 2 (2.6) 2 (2.5) 0
Diarrhea 3 (3.7) 5 (6.6) 2 (2.5) 0
Urticaria 1 (1.2) 5 (6.6) 0 0
Dizziness 8 (9.9) 0 3 (3.7) 0
Renal-related adverse events
Proteinuria 0 1 (1.3) 0 1 (1.3)
Phosphate , 2.5 mg/dL 9 (11.1) 16 (21.1) 6 (7.4) 5 (6.6)
eGFR , 50 mL/min 1 (1.2) 2 (2.6) 0 1 (1.3)
Bone related adverse events
Fracturea 2 (2.5) 1 (1.3) 1 (1.2) 0
Total-carnitine level at week 144
Decrease 1 (1.2) 1 (1.3) — —
Increase 31 (38.3) 28 (36.8) — —
Data are expressed as n (%), unless stated otherwise.
ALT, Alanine aminotransferase; BSV, besifovir dipivoxil maleate; eGFR, estimated glomerular filtration rate; TDF, tenofovir disoproxil fumarate.
aAdverse event due to trauma or accident.





response rates between both the groups when considering
HBeAg-positive patients.
Virological breakthrough and resistance surveillance. Both
groups showed no antiviral resistance for 144 weeks. The pro-
portions of patients who experienced virological breakthrough
between 96 and 144 weeks were 4.9% (4/81) in the BSV-BSV
group and 7.9% (6/76) in the TDF-BSV group, with no significant
difference between the groups. However, serum HBV DNA be-
came undetectable in all these patients without modifying the
therapy during follow-up. DNA sequencing was performed for
patients who experienced a virological breakthrough, confirming
that newmutations that caused by amino acid substitutions were
not detected in the HBV conserved sites.
Noninvasive fibrosis markers: FIB-4 and APRI. The FIB-4 and
APRI indexes significantly improved at 144 weeks vs baseline in
both groups (Table 3; see Table, Supplementary Digital Content
7, http://links.lww.com/AJG/B485). FIB-4 improved from 2.12 to
1.32 and APRI from 2.12 to 0.4 in the BSV-BSV group. Likewise,
FIB-4 improved from 1.92 to 1.27 and APRI from 1.35 to 0.39 in
the TDF-BSV group, respectively (all P , 0.001). According to
these results, the degree of hepatic fibrosis significantly decreased
in both the BSV-BSV and TDF-BSV groups over the duration of
drug administration. There was no significant difference in FIB-4
and APRI values between both the groups.
Safety
Adverse events. After reporting AEs during the 96-week study
(13), 3 serious AEs occurred: HCC in one patient from the BSV-
BSV group and HCC and type 2 diabetes mellitus in 2 patients of
the TDF-BSV group (Table 4). However, the investigator con-
firmed that all 3 patients could continue the study. No serious
adverse drug reactions or death was newly reported during
96–144 weeks in the study. L-carnitine levels were measured
during every follow-up visit. These levels were stably main-
tained, with only one patient in each group exhibiting a de-
creased level.
The median changes in eGFR from the baseline were20.5,20.7,
and20.5 mL/min at 48, 96, and 144 weeks, respectively, for the BSV-
BSV group, indicating no effect of BSV on renal function. On the
contrary, for the TDF-BSV group, the median changes in eGFR levels
from baseline were27.8,20.4, and20.8 mL/min at 48, 96, and 144
weeks, respectively; therefore, the recovered renal function after
switching to BSV at 49 weeks was maintained up to 144 weeks
(Figure 4). There was no incidence of acute kidney injury in the 2
groups.
The mean percent change in spine BMD from the baseline to
week 144 was20.02% (95% CI:22.25 to 2.22) for the BSV-BSV
(P5 0.59) and20.31% (95%CI:22.37 to 1.74) for the TDF-BSV
(P5 0.93) group. This difference was not significant (Figure 5a).
The mean percent change in hip BMD from the baseline to
week 144 was 20.42% (95% CI: 21.53 to 0.7) for the BSV-BSV
(P5 0.10) and 0.78% (95% CI:21.21 to 2.77) for the TDF-BSV
group. This difference was not significant (Figure 5b).
DISCUSSION
The incidence of HBV infection is decreasing worldwide be-
cause of improved socioeconomic status, universalization of
vaccine programs, and effective antiviral treatments (1,4).
However, population movements are now affecting the occur-
rence and prevalence of HBV in several low-endemic countries
Figure 4.Median changes from baseline in eGFR (MDRD) by study week.
Data are presented as median (Q1, Q3) values (mL/min). BSV, besifovir
dipivoxil maleate; eGFR, estimated glomerular filtration rate; MDRD,
modification of diet in renal disease; TDF, tenofovir disoproxil fumarate.
Figure 5. Changes in BMD. (a) Mean percentage changes in the spine at weeks 48, 96, and 144 of treatment. Bars represent 95% confidence interval. (b)
Mean percentage changes in the hip at weeks 48, 96, and 144 of treatment. Bars represent 95% confidence intervals. BMD, bone mineral density; BSV,
besifovir dipivoxil maleate; TDF, tenofovir disoproxil fumarate.
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(14–17). Unlike most infectious diseases, deaths from HBV-
related liver cirrhosis and/or HCC increased between 1990 and
2013 (18).
BSV, the newest approved agent in the NA class in Korea, is
currently recommended as the first-line oral agent for CHB
treatment by the Korean Association for the Study of the Liver
(19). Our study followed the CHB treatment with BSV for 144
weeks, with findings consistent with those of our previous 96-
week study (13). In total, 89.8% and 82.8% of patients had
HBV DNA,69 and,20 IU/mL, respectively, indicating that
the antiviral effect of BSV was maintained up to 144 weeks.
Reduction in hip and spine BMD was observed in patients
treated with TDF for 48 weeks, but it returned to the baseline
level after switching to BSV, and it was maintained up to 144
weeks. BSV treatment also showed a favorable safety profile
regarding renal parameters. No viral resistance was detected
during the course of the 144-week treatment. We also con-
firmed the improvement of fibrosis applying the FIB-4 and
APRI tests.
A recent 3–year study showed that TAF was associated with
a lower risk of BMD decline and nephrotoxicity (20). The mean
BMDs decreased from the baseline to week 144 of therapy (hip:
22.49 vs20.41, P, 0.001; spine:22.01 vs20.51, P, 0.001; in
TDF and TAF groups, respectively). We also observed a signif-
icant decrease in BMD in the TDF group relative to that in the
BSV group at 48 weeks. However, in the group of patients re-
ceiving BSV for 144 weeks, the BMD mean changes from the
baseline were 20.42 (hip) and 0.02 (spine), similar to those
results obtained with TAF. Treatment with BSV and TAF also
showed similar trends in eGFR changes over 3 years (eGFRMDRD
for BSV,20.5 vs eGFRCG for TAF,21.2). Although it is difficult
to perform a direct comparison between BSV and TAF treat-
ments, they seem to be similar for preserving renal function and
bone density.
Improvements in fibrosis after antiviral treatment have been
previously reported by histology (21,22). Although liver biopsy is
the accepted standard method for the assessment of hepatic fi-
brosis, repeated evaluations are difficult to perform because of
cost, the risk of life-threatening complications, and a lack of
available expertise (23–25). Therefore, we analyzed the extent of
liver fibrosis using FIB-4 andAPRI as biomarkers, as indicated by
previous studies (26–28). Importantly, in 2 noninvasive fibrosis
tests, our results showed a clear fibrosis improvement on BSV
administration.
Carnitine depletion was the most common side effect of
BSV (11,12). Therefore, BSV was supplemented with 660 mg
of L-carnitine. Carnitine concentrations were closely moni-
tored during the study period and at week 144. Except for one
patient in each group who evidenced an increase in carnitine
levels, patients were generally stably maintained with the
supplementation and none experienced clinical features of
carnitine deficiency, such as hypoglycemia, hypoketosis, and
encephalopathy.
This study has several limitations. Although the general
safety concerns related to nephrotoxicity can be ignored in the
BSV group considering the rate of decline of eGFR, additional
markers related to renal function, such as urinary albumin,
fractional excretion of uric acid, and urinary beta-2 micro-
globulin, were not evaluated. Moreover, no assessments of bone
turnover markers for the estimation of bone formation or re-
sorption were performed, although it is recommended for
patients receiving these NAs. Although noninvasive fibrosis
markers were evaluated to demonstrate the improvement of
liver fibrosis, histological analysis did not confirm such im-
provement; this calls for further evaluation. However, to our
knowledge, this is the first study reporting antiviral effects of
BSV providing safe renal and bone profile for an extended
treatment period.
In summary, BSV treatmentmaintained antiviral efficacy over
144-week period without any viral resistance. BSV administra-
tion was safe, well-tolerated, and effective for treatment-näıve
patients with CHB as well as those who switched from TDF to
BSV treatment.
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